Table 1.
Top FKBP5 SNP association results (P < 0.05) for response, remission, and percentage change in QIDS-C after SSRI treatment (on the basis of logistic regression adjustment for four eigen vectors)
| FKBP5 SNP | Location | Position | Response (last visit)
|
Response (8 weeks)
|
Percentage change in QIDS
|
|||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI)a | P-valuea | OR (95% CI)a | P-valuea | Spearmana | P-valuea | |||
| FKBP5 SNPs associated with the response outcome and percentage change in QIDS-C after SSRI treatment (P < 0.05) | ||||||||
| rs9380524 | Intron 3 | 35589070 | 0.65 (0.44–0.95) | 0.025 | 0.59 (0.38–0.91) | 0.02 | NS | NS |
| 35758265 | Intron 1 | 35650287 | NS | NS | NS | NS | 0.09 | 0.042 |
| FKBP5 SNP | Location | Position | Remission (last visit)
|
Remission (8 weeks only)
|
||||
| OR (95% CI)a | P-valuea | OR (95% CI)a | P-valuea | |||||
|
| ||||||||
| FKBP5 SNPs associated with the remission outcome after SSRI treatment (P < 0.05) | ||||||||
| 35658181 | Intron 8 | 35550203 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| 35660167 | Intron 8 | 35552189 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| 35673999 | Intron 5 | 35566021 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| 35678460 | Intron 5 | 35570482 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| 35686829 | Intron 5 | 35578851 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| 35689604 | Intron 5 | 35581626 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs11966198 | Intron 5 | 35575656 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs16878806 | Intron 5 | 35569119 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs16879318 | Intron 3 | 35590391 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs28675670 | Intron 3 | 35601529 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs34866878 | Exon 10 | 35544942 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs41270080 | 3′UTR | 35542045 | 2.34 (0.99–5.54) | 0.05 | 3.22 (1.13–9.17) | 0.02 | ||
| rs45586932 | Intron 10 | 35543995 | NS | NS | 3 (1.04–8.61) | 0.03 | ||
| rs59320339 | Intron 8 | 35550915 | NS | NS | 3 (1.04–8.61) | 0.03 | ||
| rs16878591 | Intron 8 | 35552627 | NS | NS | 3 (1.04–8.61) | 0.03 | ||
| 35692412 | Intron 5 | 35584434 | NS | NS | 3 (1.04–8.61) | 0.03 | ||
| 35702644 | Intron 3 | 35594666 | NS | NS | 3 (1.04–8.61) | 0.03 | ||
| rs12110366 | Intron 2 | 35610340 | NS | NS | 2.98 (1.04–8.56) | 0.03 | ||
| 35672403 | Intron 6 | 35564425 | NS | NS | 3.21 (1.13–9.14) | 0.03 | ||
| 35751398 | Intron 1 | 35643420 | NS | NS | 3.46 (1.09–11) | 0.04 | ||
| rs2092427 | Intron 1 | 35622207 | NS | NS | 2.99 (1.04–8.61) | 0.05 | ||
| 35696209 | Intron 3 | 35588231 | NS | NS | 3.22 (1.13–9.17) | 0.02 | ||
Highlighted in bold are the SNPs selected for replication study.
CI, confidence interval; OR, odds ratio; QIDS-C, Quick Inventory of Depressive Symptomatology-Clinician Rated; SNP, single nucleotide polymorphism; SSRI, selective serotonin reuptake inhibitor.
a
Adjusted for population stratification.